- Investing Ideas
- /
- Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
7
Companies with a Value score of at least 3, ordered by Value score
7 companies
H. Lundbeck
Market Cap: DKK 43.1b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN B
DKK 45.54
7D
1.4%
1Y
5.7%
Genmab
Market Cap: DKK 118.6b
A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
GMAB
DKK 1,927.50
7D
5.6%
1Y
19.3%
Novo Nordisk
Market Cap: DKK 1.5t
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
NOVO B
DKK 344.65
7D
-8.0%
1Y
-56.8%
H. Lundbeck
Market Cap: DKK 43.1b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN A
DKK 35.25
7D
-2.1%
1Y
-4.9%
Bavarian Nordic
Market Cap: DKK 17.9b
Develops, manufactures, and supplies life-saving vaccines.
BAVA
DKK 228.40
7D
-1.1%
1Y
2.5%
Gubra
Market Cap: DKK 6.4b
A biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.
GUBRA
DKK 389.60
7D
-5.1%
1Y
-18.2%
Zealand Pharma
Market Cap: DKK 32.5b
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States.
ZEAL
DKK 461.10
7D
1.2%
1Y
-43.1%